Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Carrie L. Langstraat, MD, a gynecologic oncologist at Mayo Clinic, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Lansgtraat highlighted findings from a retrospective study in Ohio. The study was able to demonstrate that patients with endometrial cancers who had para-aortic lymph node involvement in addition to pelvic node involvement had worse survival compared with those who had early pelvic nodal involvement.
According to Langstraat, these data are marginal, but there is a decrease in survival for patients with para-aortic lymph node involvement.
<< View more resources and information regarding gynecologic cancers
PROs Strengthen Case for Mirvetuximab Soravtansine as SOC in FRα+ Ovarian Cancer
March 16th 2024Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.
Read More